BioCorRx (BICX) Common Equity (2010 - 2026)

BioCorRx has disclosed Common Equity across 17 years of filings, most recently posting -$11.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$11.5 million, up 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.5 million (up 2.98% YoY), and the FY2025 annual result was -$11.2 million, up 9.16% from the prior year.
• Common Equity came in at -$11.5 million for Q1 2026 at BioCorRx, down from -$11.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$6.8 million in Q1 2022 to a low of -$12.4 million in Q3 2025.
• The 5-year median for Common Equity is -$10.4 million (2023), against an average of -$10.0 million.
• Across the five-year window, Common Equity tumbled 93.72% in 2022 and grew 9.16% in 2025, its largest moves.
• BioCorRx's Common Equity stood at -$8.2 million in 2022, then decreased by 21.35% to -$10.0 million in 2023, then retreated by 24.14% to -$12.4 million in 2024, then gained by 9.16% to -$11.2 million in 2025, then decreased by 2.02% to -$11.5 million in 2026.
• The last three Common Equity figures came in at -$11.5 million (Q1 2026), -$11.2 million (Q4 2025), and -$12.4 million (Q3 2025), per Business Quant data.